If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
origin of replication (ORI) Also replication origin or simply origin. A particular location within a DNA molecule at which DNA replication is initiated. Origins are usually defined by the presence of a particular replicator sequence or by specific chromatin patterns.
Romania is a country in Central and Southeastern Europe. It lies on the lower course of the Danube, north of the Balkan Peninsula, and on the northwestern shore of the Black Sea. It borders Ukraine to the north and east, Hungary to the west, Serbia to the southwest, Bulgaria to the south, Moldova to the east, and the Black Sea to the southeast. It is the twelfth-largest country in Europe by area, covering 238,397 km2 (92,046 mi2), and the sixth-most populous member state of the European Union, with 19 million inhabitants. Administratively, Romania is divided into 41 counties, the largest being Timiș County. The capital, largest city and economic centre is Bucharest. Other major cities and metropolitan areas include Timișoara (TMA), Iași (IMA), Constanța (CMA) and Cluj-Napoca (CMA). Romania was settled during the Lower Paleolithic, later becoming Dacia before Trajan's Dacian Wars and Romanisation. The modern Romanian state was formed in 1859 with the unification of Moldavia and Wallachia under Alexandru Ioan Cuza, becoming the Kingdom of Romania in 1881 under Carol I of Romania. Romania gained independence from the Ottoman Empire in 1877, formalised by the Treaty of Berlin. After World War I, Transylvania, Banat, Bukovina, and Bessarabia joined the Old Kingdom, forming Greater Romania, which reached its largest territorial extent. In 1940, under Axis pressure, Romania lost territories to Hungary, Bulgaria, and the Soviet Union. Following the Act of 23 August, Romania switched sides to join the Allies.
Comecon Frascati Manual German Marshall Fund Good laboratory practice International organisations in Europe International Transport Forum List of country groupings List of multilateral free trade agreements Marshall Plan OECD Anti-Bribery Convention OECD Better Life Index OECD Environmental Performance Reviews OECD Working Party on SMEs and Entrepreneurship Official development assistance Organization for Security and Co-operation in Europe Transfer pricing
=== Modern corals === The currently ubiquitous stony corals, Scleractinia, appeared in the Middle Triassic to fill the niche vacated by the extinct rugose and tabulate orders and is not closely related to the earlier forms. Unlike the corals prevalent before the Permian extinction, which formed skeletons of a form of calcium carbonate known as calcite, modern stony corals form skeletons composed of aragonite. Their fossils are found in small numbers in rocks from the Triassic period, and become common in the Jurassic and later periods. Although they are geologically younger than the tabulate and rugose corals, the aragonite of their skeletons is less readily preserved, and their fossil record is accordingly less complete.
== Medical uses == Cinnarizine is predominantly used to treat nausea and vomiting associated with motion sickness, vertigo, Ménière's disease, or Cogan's syndrome. It is one of only a few drugs that has a beneficial effect in the chronic treatment of the vertigo and tinnitus associated with Ménière's disease. In a clinical study (n=181), treatment with cinnarizine reduced the occurrence of moderate vertigo experience by 65.8% and extreme vertigo by 89.8%.
Sources: en.wikipedia.org
Before receiving his permanent prison assignment, Noriega was placed in the Federal Detention Center, Miami. Noriega was incarcerated in the Federal Correctional Institution, Miami. Under Article 85 of the Third Geneva Convention, Noriega was considered a prisoner of war, despite his conviction for acts committed prior to his capture by the "detaining power" (the U.S.). This status meant that he had his own prison cell, furnished with electronics and exercise equipment. His cell was nicknamed "the presidential suite". While Noriega was in prison, he was visited regularly over two years by two evangelical Christian ministers, Clift Brannon and Rudy Hernandez. Noriega, nominally a Roman Catholic, was reported to have undergone a conversion to evangelical Christianity in May 1990, and was baptized in October 1992, while still in prison. Noriega's prison sentence was reduced from 40 to 30 years by the judge, then to 17 years for good behavior. His U.S. sentence thus ended on September 9, 2007, though his incarceration ended up being extended while extradition requests by other countries were being adjudicated.
Chronic granulomatous disease (CGD), also known as Bridges–Good syndrome, chronic granulomatous disorder, and Quie syndrome, is a diverse group of hereditary diseases in which certain cells of the immune system have difficulty forming the reactive oxygen compounds (most importantly the superoxide radical due to defective phagocyte NADPH oxidase) used to kill certain ingested pathogens. This leads to the formation of granulomas in many organs. CGD affects about 1 in 200,000 people in the United States, with about 20 new cases diagnosed each year. This condition was first discovered in 1950 in a series of four boys from Minnesota, and in 1957 it was named "a fatal granulomatosus of childhood" in a publication describing their disease. The underlying cellular mechanism that causes chronic granulomatous disease was discovered in 1967, and research since that time has further elucidated the molecular mechanisms underlying the disease. Bernard Babior made key contributions in linking the defect of superoxide production of white blood cells, to the cause of the disease. In 1986, the X-linked form of CGD was the first disease for which positional cloning was used to identify the underlying genetic mutation.
In pharmacokinetics, the effective half-life is the rate of accumulation or elimination of a biochemical or pharmacological substance in an organism; it is the analogue of biological half-life when the kinetics are governed by multiple independent mechanisms. This is seen when there are multiple mechanisms of elimination, or when a drug occupies multiple pharmacological compartments. It reflects the cumulative effect of the individual half-lives, as observed by the changes in the actual serum concentration of a drug under a given dosing regimen. The complexity of biological systems means that most pharmacological substances do not have a single mechanism of elimination, and hence the observed or effective half-life does not reflect that of a single process, but rather the summation of multiple independent processes.
Under the influence of androgens, the larynx (or voice box) grows in both sexes. This growth is far more prominent in males, causing the male voice to drop and deepen, sometimes abruptly but rarely "overnight", about one octave, because the longer and thicker vocal folds have a lower fundamental frequency. Before puberty, the larynx of males and females is about equally small.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.